Quoin Pharmaceuticals Ltd. (QNRX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $4.15
- As of
Kresmion compiles this page from QNRX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Quoin Pharmaceuticals Ltd. (QNRX): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-14.
See the full QNRX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for QNRX on one page. Preview it with sample data, then open it live with a free account.
Preview the QNRX dossierActive signals for QNRX
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 15.7%, EPS $-1.90 vs $-1.6422 estimate
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 16.9% - EPS $-6.28 vs $-7.5582 estimate
- mediumEARNINGS_MISS
Q3-2025: Missed consensus by 32.2% - EPS $-6.71 vs $-5.0762 estimate
- mediumEARNINGS_BEAT
Q4-2025: Beat consensus by 55.9% - EPS $-1.5 vs $-3.4034 estimate
- mediumEARNINGS_BEAT
Q1-2026: Beat consensus by 9.9% - EPS $-1.77 vs $-1.9652 estimate
FREE, NO ACCOUNT
Every signal on QNRX, as it fires
New filings, 13F moves and cross asset signals on QNRX land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in QNRX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 74907L409 · 2026Q2 | $544K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, QNRX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
QNRX against its peers
QNRX's return on equity of -120.5% ranks in the 47th percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-10-31 and 2026-06-30.
| Metric | QNRX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 3.1M | n/a | 9 |
| Operating margin | n/a | -1315.4% | n/a | 9 |
| Net margin | n/a | -1145.7% | n/a | 9 |
| Return on equity | -120.5% | -113.4% | 47 | 17 |
| 1 year | -72.1% | -79.0% | 53 | 15 |
Peers (20): TCRX, PVCT, COCP, ATOS, CMND, CNTX, ESLA, NXTC, JSPR, ACTU, KYNB, AKTX, VYNE, NEUP, SNSE, HOTH, ABVC, DYAI, PSTV, MRKR. Left out: QNTM (no annual filing), PLRZ (no annual filing), PBM (period gap), TTIPF (no annual filing), RADX (no annual filing). Fiscal periods ending between 2025-10-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (QNRX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow QNRX on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to QNRX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.